These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34544301)

  • 1. Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis.
    Gauthier G; Levin R; Vekeman F; Reyes JM; Chiarello E; Ponce de Leon D
    Curr Med Res Opin; 2021 Dec; 37(12):2185-2196. PubMed ID: 34544301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years.
    Sánchez-Piedra C; Sueiro-Delgado D; García-González J; Ros-Vilamajo I; Prior-Español A; Moreno-Ramos MJ; Garcia-Magallon B; Calvo-Gutiérrez J; Perez-Vera Y; Martín-Domenech R; Ruiz-Montesino D; Vela-Casasempere P; Expósito L; Sánchez-Alonso F; González-Davila E; Díaz-González F
    Sci Rep; 2021 Jul; 11(1):15051. PubMed ID: 34302036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases.
    Sheahan A; Anjohrin S; Suruki R; Stark JL; Sloan VS
    Clin Rheumatol; 2024 Jun; 43(6):1897-1907. PubMed ID: 38658403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in Poland: a nation-level study.
    Stajszczyk M; Kwiatkowska B; Żuber ZM; Batko B
    Pol Arch Intern Med; 2024 Apr; 134(4):. PubMed ID: 38165391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
    Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
    Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry.
    Sørensen J; Hetland ML;
    Ann Rheum Dis; 2015 Mar; 74(3):e12. PubMed ID: 24534758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA.
    Hunter T; Grabner M; Birt J; Isenberg K; Shan M; Teng CC; Wu J; Griffing K; Lisse J; Curtis JR
    Clin Rheumatol; 2022 Sep; 41(9):2863-2874. PubMed ID: 35672618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study.
    Miler M; Nikolac Gabaj N; Grazio S; Vahtarić A; Vrtarić A; Grubišić F; Skala Kavanagh H; Doko Vajdić I; Vrkić N
    Rheumatol Int; 2020 Sep; 40(9):1455-1461. PubMed ID: 32462255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world.
    Sung YK; Jung SY; Kim H; Choi S; Im SG; Lee YS; Jang EJ; Cho SK
    PLoS One; 2020; 15(1):e0227960. PubMed ID: 31978121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry.
    Prior-Español A; Sánchez-Piedra C; Campos J; Manero FJ; Pérez-García C; Bohórquez C; Busquets-Pérez N; Blanco-Madrigal JM; Díaz-Torne C; Sánchez-Alonso F; Mateo L; Holgado-Pérez S
    Sci Rep; 2021 May; 11(1):11091. PubMed ID: 34045525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
    Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G; Strehblow C; Fasching P
    Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.